Iron Substitution in Blood Donors (ISUB)
Primary Purpose
Fatigue
Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Iron carboxymaltose (Ferinject)
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Fatigue focused on measuring Anemia, Iron-Deficiency, Blood Donors
Eligibility Criteria
Inclusion Criteria:
- Serum-Ferritin 50 microg/l
- Eligibility for blood donation
- At least one prior blood donation
Exclusion Criteria
- Anemia
- Known intolerability of intravenous iron
- History of anaphylactic reactions
- Active systemic infections
- Signs of chronic bleeding
- Known iron overload
- Lactation
- Pregnancy
- Any disease associated with increased fatigue
- Medication associated with increased fatigue
Sites / Locations
- Department of Hematology, Bern University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Verum
Placebo
Arm Description
Iron Carboxymaltose (Ferinject)
0.9% NaCl solution
Outcomes
Primary Outcome Measures
Difference of fatigue on a 10 point numeric scale after intravenous substitution of iron or placebo
measured by questionnaire
Secondary Outcome Measures
Change of fatigue after intravenous substitution of iron
measured by questionnaire
Improvement of general wellbeing
measured by questionnaire
Number of patients with adverse events of different grades
Full Information
NCT ID
NCT01519830
First Posted
January 16, 2012
Last Updated
February 27, 2013
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
Blutspendedienst SRK Bern AG, 3008 Bern, Switzerland, University of Bern, Humanitäre Stiftung des Schweizerischen Roten Kreuzes, 3011 Bern, Switzerland
1. Study Identification
Unique Protocol Identification Number
NCT01519830
Brief Title
Iron Substitution in Blood Donors
Acronym
ISUB
Official Title
Significance of Iron Deficiency in Transfusion Medicine: Effects of Iron Substitution on Fatigue Und General Well Being in Healthy Blood Donors
Study Type
Interventional
2. Study Status
Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
Blutspendedienst SRK Bern AG, 3008 Bern, Switzerland, University of Bern, Humanitäre Stiftung des Schweizerischen Roten Kreuzes, 3011 Bern, Switzerland
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Depletion of iron stores is frequently observed in regular blood donors, but effects of iron deficiency on general health is not well studied. Recent studies in women suffering of fatigue suggest iron deficiency without concomitant anemia as a common cause of these complaints. Provided the same is true in healthy subjects, substitution of intravenous iron might result in an improvement of general well being in iron depleted blood donors.
Healthy regular blood donors will be screened for low storage iron. Qualifying subjects will be invited to participate in a randomized, placebo-controlled trial with substitution of intravenous iron or placebo (saline solution). Differences in subjectively felt fatigue and other factors of general health and well being will be assessed. If an improvement of such factors can be shown after iron replacement, relevant concerns about artificially lowering iron stores by repeated phlebotomies will arise and changes of monitoring and substitution policies in blood banking might have to be discussed.
Detailed Description
Background
Chronic iron deficiency causes anemia with impairment of physical and mental capacity. Since iron plays an essential role in many enzymes apart from oxygen carriage, iron deficiency was proposed as an independent factor impairing wellbeing also without anemia. Symptoms like fatigue, asthenia, physical weakness, mental impairment and many others have been associated with iron deficiency. Recent clinical trials with iron substitution in iron deficient women suffering of general fatigue support this hypothesis, but data are still conflicting and debated.
Low body iron stores are frequently observed in blood donors. Repeated phlebotomies may induce or aggravate severe iron deficiency. Astonishingly, little is known about the long term effects of reduced iron stores on general health of regular blood donors. Serious health impairment cannot be excluded conclusively. Since many symptoms associated with iron deficiency are subtle, they might be missed by otherwise healthy subjects.
Blood donors with borderline or decreased iron stores (i.e. serum ferritin below 50 microg/l) will be invited to participate in a randomized, placebo-controlled intervention study comparing intravenous iron carboxymaltose and a physiological saline solution (placebo). Subjectively felt fatigue, measured on a numeric rating scale from 1 to 10 as the major end point will be assessed before and six months after application of the study drug. As additional factors, various aspects of general wellbeing will be assessed using four psychometric questionnaires. Statistical analysis will compare the results before and after application of the study drug and the results of the two study arms.
Objective
Assessment of severity of iron deficiency in a large group of blood donors.
Demonstration of an improvement of fatigue after substitution of iron compared with placebo in iron deficient blood donors
Detection of improved general wellbeing in otherwise healthy blood donors after substitution of intravenous iron
Assessment of tolerability of intravenous iron in healthy blood donors
Methods
Randomized, placebo controlled interventional trial comparing the effect of intravenous iron or placebo on fatigue and various other factors of general wellbeing. Endpoints assessed on a numeric rating scale from 1 to 10 and four psychometric questionnaires.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fatigue
Keywords
Anemia, Iron-Deficiency, Blood Donors
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
405 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Verum
Arm Type
Experimental
Arm Description
Iron Carboxymaltose (Ferinject)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
0.9% NaCl solution
Intervention Type
Drug
Intervention Name(s)
Iron carboxymaltose (Ferinject)
Intervention Description
Intravenous iron
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
0.9% NaCl solution
Primary Outcome Measure Information:
Title
Difference of fatigue on a 10 point numeric scale after intravenous substitution of iron or placebo
Description
measured by questionnaire
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Change of fatigue after intravenous substitution of iron
Description
measured by questionnaire
Time Frame
6 weeks
Title
Improvement of general wellbeing
Description
measured by questionnaire
Time Frame
6 weeks
Title
Number of patients with adverse events of different grades
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Serum-Ferritin 50 microg/l
Eligibility for blood donation
At least one prior blood donation
Exclusion Criteria
Anemia
Known intolerability of intravenous iron
History of anaphylactic reactions
Active systemic infections
Signs of chronic bleeding
Known iron overload
Lactation
Pregnancy
Any disease associated with increased fatigue
Medication associated with increased fatigue
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Keller, MD
Organizational Affiliation
Department of Hematology, Bern University Hospital, Switzerland
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Bernhard Lämmle, MD, Prof.
Organizational Affiliation
Department of Hematology, Bern University Hospital, Switzerland
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Stefano Fontana, MD
Organizational Affiliation
Blutspendedienst SRK Bern AG, Bern, Switzerland
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Peter Jüni, MD, Prof.
Organizational Affiliation
Institut für Sozial- und Präventivmedizin, Universität Bern, Switzerland
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Roland von Känel, MD, Prof.
Organizational Affiliation
Kompetenzbereich für Psychosomatische Medizin, University Hospital Bern
Official's Role
Study Chair
Facility Information:
Facility Name
Department of Hematology, Bern University Hospital
City
Bern
ZIP/Postal Code
CH-3010
Country
Switzerland
12. IPD Sharing Statement
Learn more about this trial
Iron Substitution in Blood Donors
We'll reach out to this number within 24 hrs